IOL Chemicals & Pharmaceuticals Reports Q2 & H1 FY26 Results: 56.7% PAT Growth, Strategic Progress in Pharmaceuticals and Chemicals Business

IOL Chemicals & Pharmaceuticals Ltd., one of the leading manufacturers of Bulk Drugs & Specialty Chemicals, announced its Financial Results for the quarter and half year ended 30 September 2025. The company reported a 56.7% Y-o-Y increase in Profit After Tax (PAT) to 30.0 Cr, driven by better operating leverage and cost efficiencies. EBITDA improved by 33.3% Y-o-Y to 64.0 Cr, with EBITDA margin expanding to 11.1% from 9.0%. Revenue from Operations rose by 7.9% Y-o-Y to 567.5 Cr. The Pharmaceuticals segment gained momentum, led by strong traction in non-Ibuprofen APIs. IOL Chemicals and Pharmaceuticals incorporated IOL Pharmaxis UK Limited in October 2025 to strengthen international operations in Pharmaceuticals and Chemicals business and expand its global reach. The company also received EDQM's Certificate of Suitability for Pantoprazole Sodium Sesquihydrate Process-Ill on 14th October 2025, enabling exports to Europe and CEP-compliant markets.